Cadonilimab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: In combination with fluoropyrimidine and platinum-based chemotherapy, first-line... (CN)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Weak signal

Also in development:Cervical Cancer · Phase 3 · investigational in the USHepatocellular Carcinoma · Phase 3 · investigational in the US

Also approved (2)
CN
  • In combination with fluoropyrimidine and platinum-based chemotherapy, first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinomaOutside this platform's coverageakesobio.com
  • Recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapywww1.hkexnews.hk
Product first approved 2022

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Cervical Cancer
NCT05235516 · Akeso
2022-06-21 – 2029-05 · Locally Advanced Cervical Carcinoma
What this study did
Hepatocellular Carcinoma
NCT05489289 · Akeso
2023-01-05 – 2027-01-01 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07400536 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-04-24 – 2032-07-20 · Locally Advanced Cervical Carcinoma
What this study did
NCT07023315 · Akeso
2025-08-14 – 2031-07 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT07412613 · Akeso
2026-04-15 – 2031-03-15 · Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
What this study did
NCT07815834 · Fudan University
2026-10-01 – 2031-03-01 · Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy, Immunotherapy
What this study did
NCT06949033 · Zuoyi Jiao
2025-05-15 – 2030-12-31 · Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR, ORR,OS,PFS
What this study did
NCT06542549 · Anhui Provincial Hospital
2025-03-11 – 2030-10-31 · Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, Safety
What this study did
NCT05941741 · Sun Yat-sen University
2024-01-10 – 2029-12 · Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
What this study did
NCT05587374 · Sun Yat-sen University
2023-08-01 – 2029-08-01 · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
What this study did
NCT06341335 · Akeso
2024-06-19 – 2027-07 · Gastric and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06566755 · Caigang Liu
2024-02-01 – 2027-02-01 · Colorectal Cancer
What this study did
NCT06664983 · Sun Yat-sen University
2024-10-21 – 2026-10-21 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT05008783 · Akeso
2021-09-17 – 2025-08-01 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT06241599 · Sun Yat-sen University
2024-02-01 – 2029-02-01 · Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
NCT06221748 · RemeGen Co., Ltd.
2024-02-22 – 2027-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (143)
Cervical Cancer
NCT07450963 · Ruijin Hospital
2026-03 – 2034-02 · Locally Advanced Cervical Cancer
What this study did
NCT06289751 · Tongji Hospital
2024-09-03 – 2031-01-01 · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
What this study did
NCT07649174 · Obstetrics & Gynecology Hospital of Fudan University
2026-06-06 – 2030-12-31 · Cervical Cancer
What this study did
NCT06511726 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-23 – 2029-04-30 · Cervical Cancer
What this study did
NCT06209294 · Xiaohua Wu
2023-09-01 – 2028-12-30 · Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery
What this study did
NCT06998394 · Xiangbo Wan
2025-03-12 – 2027-12-31 · Cervical Cancer Stage IV
What this study did
NCT07104149 · The First Affiliated Hospital of Zhengzhou University
2025-03-10 – 2027-06-30 · Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion, Sufficient Organ Function, The Result of the Urine or Serum Pregnancy Test for the Subject is Negative, Subjects Should Take Contraceptive Measures, Locally Advanced Cervical Cancer, Expected Survival Time >6 Months
What this study did
NCT05817214 · Zhongnan Hospital
2023-02-16 – 2027-02-28 · Cervical Cancer
What this study did
NCT05687851 · Chongqing University Cancer Hospital
2022-12-29 – 2026-12 · Locally Advanced Cervical Cancer
What this study did
NCT05063916 · M.D. Anderson Cancer Center
2022-02-28 – 2026-11-11 · Carcinomas, Cervix Cancer, Cervical Cancer
What this study did
NCT06251388 · West China Second University Hospital
2024-02-20 – 2026-10-01 · Cervical Cancer
What this study did
NCT05824494 · Women's Hospital School Of Medicine Zhejiang University
2023-06 – 2026-06 · Uterine Cervical Neoplasms, Cancer of Cervix, Cervical Cancer, Cervical Neoplasms, Uterine Cervical Cancer, Cancer of the Uterine Cervix
What this study did
NCT06455046 · Fujian Cancer Hospital
2023-10-11 – 2025-10-10 · Cervical Cancer Recurrent
What this study did
NCT05227651 · Akeso
2023-02-10 – 2024-09-27 · Cervical Cancer
What this study did
NCT04868708 · Akeso
2021-04-01 – 2024-02-28 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT04380805 · Akeso
2020-07-15 – 2023-01-31 · Recurrent Cervical Cancer, Metastatic Cervical Cancer
What this study did
Hepatocellular Carcinoma
NCT06789848 · University of Texas Southwestern Medical Center
2025-02-18 – 2030-05-31 · Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
NCT06187961 · Tongji Hospital
2023-12-30 – 2028-07-20 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT07243951 · Shanghai Zhongshan Hospital
2025-11-28 – 2028-06-30 · Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms
What this study did
NCT07052253 · Akeso
2025-07-18 – 2027-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06984718 · Akeso
2025-06-25 – 2027-06-30 · HCC, Hepatocellular Carcinoma
What this study did
NCT06361758 · Shanghai Zhongshan Hospital
2024-05-31 – 2027-05-31 · Hepatocellular Carcinoma
What this study did
NCT06406634 · Hunan Cancer Hospital
2024-05-15 – 2027-04-20 · Hepatocellular Carcinoma
What this study did
NCT06280105 · Meng Chao Hepatobiliary Hospital of Fujian Medical University
2024-03-31 – 2027-03-31 · Hepatocellular Carcinoma
What this study did
NCT06196775 · Harbin Medical University
2024-01-31 – 2027-01-31 · Hepatocellular Carcinoma
What this study did
NCT06215651 · Peking Union Medical College Hospital
2024-03-11 – 2027-01 · Cadonilimab and Lenvatinib
What this study did
NCT06851104 · Guangxi Medical University
2025-02-16 – 2025-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05882370 · Fei Gao
2022-12-01 – 2025-08-31 · Hepatocellular Carcinoma
What this study did
NCT05821361 · Tianjin Medical University Cancer Institute and Hospital
2023-08-01 – 2025-08-01 · Unrescetable Hepatocellular Carcinoma
What this study did
NCT05925413 · Eastern Hepatobiliary Surgery Hospital
2023-04-24 – 2025-07-30 · Hepatocellular Carcinoma
What this study did
NCT05319431 · Akeso
2022-06-28 – 2025-06-30 · Unresectable, Non-metastatic Hepatocellular Carcinoma
What this study did
NCT05578430 · Sun Yat-sen University
2023-01-01 – 2025-01-01 · Resectable Hepatocellular Carcinoma
What this study did
NCT04728321 · Akeso
2021-01-27 – 2023-08-02 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06946836 · Shanghai Pulmonary Hospital, Shanghai, China
2025-04-21 – 2031-05-11 · Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy
What this study did
NCT05377658 · Henan Cancer Hospital
2022-07-26 – 2027-12-31 · Non-small Cell Lung Cancer
What this study did
NCT06702826 · Rongrong Zhou
2024-11-01 – 2027-11-01 · Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
What this study did
NCT06001151 · Qian Chu
2023-08-07 – 2027-08-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06448910 · Fudan University
2024-07-01 – 2027-06 · NSCLC, Locally Advanced Lung Carcinoma
What this study did
NCT06793813 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-01-23 – 2026-12-30 · Stage IVB Lung Cancer, Non-Squamous
What this study did
NCT06532591 · Sichuan Cancer Hospital and Research Institute
2024-08-01 – 2025-10-01 · NSCLC
What this study did
NCT06331650 · Guangzhou Institute of Respiratory Disease
2023-08-09 – 2025-10 · Non-small Cell Lung Cancer
What this study did
NCT06424821 · Shanghai Pulmonary Hospital, Shanghai, China
2023-07-04 – 2025-09-04 · NSCLC
What this study did
NCT05812534 · Second Affiliated Hospital of Nanchang University
2023-12 – 2025-06 · Non Small Cell Lung Cancer, Brain Metastases
What this study did
NCT06277674 · Guangzhou University of Traditional Chinese Medicine
2023-11-02 – 2025-06 · Non-small Cell Lung Cancer
What this study did
NCT04544644 · Chinese PLA General Hospital
2020-09 – 2023-09 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07900256 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-10-01 – 2033-04-01 · Endometrial Cancer
What this study did
NCT07263919 · Akeso
2025-12-19 – 2031-12 · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
What this study did
Phase 1/2 (28)
Hepatocellular Carcinoma
NCT06530251 · Akeso
2024-09-24 – 2028-09 · Hepatocellular Carcinoma
What this study did
NCT05773105 · Sun Yat-sen University
2023-09-19 – 2026-03-30 · Advanced Hepatocellular Carcinoma
What this study did
NCT06040177 · First Affiliated Hospital of Guangxi Medical University
2023-02-02 – 2025-02-01 · Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors
What this study did
NCT04444167 · Akeso
2020-07-07 – 2023-11-20 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT05904379 · Akeso
2023-07-13 – 2027-01-31 · Advanced Non-small-cell Lung Cancer
What this study did
NCT05816499 · Shanghai Chest Hospital
2023-02-16 – 2025-12-30 · NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC
What this study did
NCT04646330 · Akeso
2020-11-18 – 2025-07-30 · NSCLC
What this study did
NCT04647344 · Akeso
2020-11-24 – 2023-12-31 · Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
What this study did
Other / comorbidity
NCT05426005 · Sun Yat-sen University
2023-02-07 – 2028-12-01 · Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)
What this study did
NCT06762080 · Guangzhou Medical University
2025-03-07 – 2028-09-30 · Leptomeningeal Metastasis
What this study did
NCT06477523 · Sichuan University
2024-05-16 – 2027-12-31 · SCLC, Extensive Stage
What this study did
NCT06650332 · Zhejiang Cancer Hospital
2024-07-10 – 2027-12-30 · Metastatic HER2 Positive Gastroesophageal Junction Cancer
What this study did
NCT06646055 · Akeso
2025-01-21 – 2027-12-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06940921 · Zhang Tao
2025-03-20 – 2027-11-30 · Advanced Gastric Cancer, Advanced Colorectal Cancer, Advanced Ovarian Cancer, Peritoneal Metastasis
What this study did
NCT06577961 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-08-31 – 2027-08-31 · Kidney Cancer, RCC, Renal Cell Carcinoma
What this study did
NCT05142423 · Akeso
2021-11-03 – 2027-04 · Advanced Solid Tumor
What this study did
NCT04982276 · Akeso
2021-08-23 – 2027-01-31 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05944224 · Shanghai Pharmaceuticals Holding Co., Ltd
2023-10-17 – 2026-12-31 · Advanced Solid Tumors
What this study did
NCT05898256 · Guangxi Medical University
2023-08-01 – 2026-07-31 · Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
What this study did
NCT05808608 · Hao Zeng
2023-11-17 – 2026-06 · Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
What this study did
NCT05235542 · Akeso
2022-03-12 – 2026-05-09 · Advanced Malignant Tumors
What this study did
NCT06586294 · Akeso
2024-09-30 – 2026-04-20 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05915481 · Peking University Third Hospital
2023-06-21 – 2025-06-21 · Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety, Efficacy
What this study did
NCT05505825 · Akeso
2022-08-26 – 2024-07-31 · SCLC,Extensive Stage
What this study did
NCT05559541 · Akeso
2022-12-15 – 2024-05-31 · Solid Tumor, Adult
What this study did
NCT03852251 · Akeso
2019-01-18 – 2024-03-25 · Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04444141 · Akeso
2020-05-15 – 2022-09-30 · Peripheral T-cell Lymphoma
What this study did
NCT04172454 · Akeso
2019-12-20 – 2022-09-23 · Advanced Solid Tumors, Melanoma
What this study did
Phase 1 (17)
Hepatocellular Carcinoma
NCT07446257 · University of Texas Southwestern Medical Center
2026-09-01 – 2030-09-01 · Resectable Hepatocellular Carcinoma
What this study did
NCT05644379 · Tianjin Medical University Cancer Institute and Hospital
2022-11-24 – 2026-11 · Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
What this study did
NCT05856864 · Tianjin Medical University Cancer Institute and Hospital
2024-06-01 – 2025-05-01 · Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
What this study did
Other / comorbidity
NCT06424626 · Peking University Cancer Hospital & Institute
2024-05-28 – 2028-12-31 · Melanoma, Mucosal Melanoma, Metastatic Melanoma
What this study did
NCT06929663 · Akeso
2025-07-02 – 2028-12-30 · Advanced Solid Tumors
What this study did
NCT06913218 · Akeso
2025-07-22 – 2028-11-06 · Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
What this study did
NCT07908147 · Olivia Newton-John Cancer Research Institute
2027-03 – 2028-03 · IDH Wildtype Glioblastoma, Glioblastoma (GBM)
What this study did
NCT07586904 · Xijing Hospital
2025-05-01 – 2027-06 · Melanoma (Skin Cancer)
What this study did
NCT07619001 · Akeso
2026-06-01 – 2026-12-30 · Healthy Male Adults Participants
What this study did
NCT05644392 · Tianjin Medical University Cancer Institute and Hospital
2022-11-25 – 2025-11-25 · Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
What this study did
NCT05021120 · Akesobio Australia Pty Ltd
2021-10-12 – 2025-04-01 · Advanced or Metastatic Solid Tumours
What this study did
NCT05737368 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-02-28 – 2025-02-28 · Recurrent Glioblastoma
What this study did
NCT04572152 · Akeso
2020-12-07 – 2023-08-31 · Advanced or Metastatic Solid Tumors
What this study did
NCT03261011 · Akesobio Australia Pty Ltd
2017-10-03 – 2023-04-13 · Advanced Cancer
What this study did
NCT05559554 · Akeso
2022-10-25 – 2023-04-06 · Healthy Male Subjects
What this study did
NCT04349969 · Akesobio Australia Pty Ltd
2020-04-23 – 2022-11-08 · Neoplasms Malignant
What this study did
Early phase / not applicable (5)
Cervical Cancer
NCT06878196 · Obstetrics & Gynecology Hospital of Fudan University
2025-03-10 – 2028-12 · Uterine Cervical Neoplasm
What this study did
Other / comorbidity
NCT06551207 · Liu Huang
2024-08-20 – 2027-12-30 · Metastatic Colorectal Cancer
What this study did
NCT06553781 · Fudan University
2024-09-01 – 2027-09-01 · Malignant Melanoma
What this study did
NCT06715501 · First Affiliated Hospital of Ningbo University
2024-12-01 – 2027-09-01 · Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages
What this study did
NCT05800080 · Xijing Hospital
2023-04 – 2025-02 · Gastric Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT07556640 · Ruijin Hospital
2026-04-17 – 2029-04-30 · Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Hepatocellular Carcinoma
NCT06265350 · Sun Yat-sen University
2024-02-02 – 2027-01-30 · Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab, Bevacizumab, Cryoablation
What this study did

Competitive landscape

This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cadonilimab: this drugPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(62 total)

Covered in the briefing Q4 2026 readouts that matter.

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cadonilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (15)
November 2026 (2)
Phase 3Gastric and Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-11 · NCT06341335 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2026-11-30 · NCT06984718 · CT.gov ↗
What to watch
December 2026 (13)
Phase 1Melanoma (Skin Cancer)Recruiting
Est. primary completion 2026-12 · NCT07586904 · CT.gov ↗
What to watch
Phase 2MSI-H/dMMR Gastric Carcinoma and Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT04556253 · CT.gov ↗
What to watch
Phase 2/3Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-12 · NCT06221748 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2026-12-01 · NCT05926700 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-30 · NCT06467500 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-30 · NCT06551207 · CT.gov ↗
What to watch
Phase 1/2SCLC, Extensive StageActive not recruiting
Est. primary completion 2026-12-31 · NCT06477523 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT05944224 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05747716 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06769971 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12-31 · NCT07104149 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07243951 · CT.gov ↗
What to watch
2027 (25)
January 2027 (2)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-01 · NCT06196697 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Stage IV, Peritoneal MetastasesRecruiting
Est. primary completion 2027-01 · NCT06519591 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Advanced Soft-tissue SarcomaRecruiting
Est. primary completion 2027-03-31 · NCT06367075 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-04 · NCT05142423 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2027-04-24 · NCT05794750 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-04-30 · NCT06349967 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersRecruiting
Est. primary completion 2027-05-01 · NCT07003022 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-06-01 · NCT06356688 · CT.gov ↗
What to watch
Phase 2Pleural MesotheliomaNot yet recruiting
Est. primary completion 2027-06-20 · NCT06416930 · CT.gov ↗
What to watch
Phase 2Previously Treated, Advanced, Biliary Tract CancersActive not recruiting
Est. primary completion 2027-06-30 · NCT07635290 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT07909265 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3Nasopharyngeal Carcinoma, Nasopharyngeal CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT05587374 · CT.gov ↗
What to watch
Phase 1/2Kidney Cancer, RCC, Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT06577961 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, SafetyRecruiting
Est. primary completion 2027-10-31 · NCT06542549 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06702826 · CT.gov ↗
What to watch
Phase 3Gastric / Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-11-17 · NCT07449780 · CT.gov ↗
What to watch
Phase 1/2Advanced Gastric Cancer, Advanced Colorectal Cancer, Advanced Ovarian Cancer, Peritoneal MetastasisActive not recruiting
Est. primary completion 2027-11-30 · NCT06940921 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2027-12 · NCT07245446 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, ChemotherapyRecruiting
Est. primary completion 2027-12 · NCT05941741 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Liver Metastases (CRLM)Recruiting
Est. primary completion 2027-12-01 · NCT07544784 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal MetastasisRecruiting
Est. primary completion 2027-12-30 · NCT06762080 · CT.gov ↗
What to watch
Phase 1Melanoma, Mucosal Melanoma, Metastatic MelanomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT06424626 · CT.gov ↗
What to watch
Phase 2Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06681285 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2027-12-31 · NCT06998394 · CT.gov ↗
What to watch
2028 (10)
February 2028 (1)
Phase 1Pancreas Cancer, Pancreas Cancer, Duct Cell AdenocarcinomaNot yet recruiting
Est. primary completion 2028-02-23 · NCT06913218 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1IDH Wildtype Glioblastoma, Glioblastoma (GBM)Not yet recruiting
Est. primary completion 2028-03 · NCT07908147 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-06-30 · NCT06929663 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 3Locally Advanced Cervical CarcinomaRecruiting
Est. primary completion 2028-07-18 · NCT07400536 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Ovary CancerRecruiting
Est. primary completion 2028-08-01 · NCT06540729 · CT.gov ↗
What to watch
December 2028 (4)
Early phase / not applicableCervical CancerNot yet recruiting
Est. primary completion 2028-12 · NCT06878196 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07649174 · CT.gov ↗
What to watch
Phase 3Rectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06832917 · CT.gov ↗
What to watch
Phase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR …Recruiting
Est. primary completion 2028-12-31 · NCT06949033 · CT.gov ↗
What to watch
2029 (7)
February 2029 (1)
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07450963 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Renal Cell Carcinoma, Clear CellNot yet recruiting
Est. primary completion 2029-04-12 · NCT07877194 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2Gastric Cancer, Gastroesophageal-junction CancerRecruiting
Est. primary completion 2029-05-27 · NCT07631000 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-05-31 · NCT06789848 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaRecruiting
Est. primary completion 2029-07 · NCT07023315 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Gastric / Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-08-18 · NCT07700979 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09-01 · NCT07446257 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
Phase 2Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-03 · NCT07263919 · CT.gov ↗
What to watch
June 2030 (1)
Phase 3Resectable Colon Cancer, MSI-H/dMMR Colorectal CancerRecruiting
Est. primary completion 2030-06-15 · NCT07412613 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy, ImmunotherapyRecruiting
Est. primary completion 2030-08-01 · NCT07815834 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-05-01 · NCT06946836 · CT.gov ↗
What to watch
2033 (1)
April 2033 (1)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2033-04-01 · NCT07900256 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 November 2023Topline resultAK104-302 (NCT05008783) Phase 3 met its primary endpoint
Akeso (9926.HK) · Source ↗